Need for the guideline SLE (or lupus) is a complex, multi-system autoimmune disease that affects nearly 1 in 1000 people in the UK [1] . Despite improvement in survival over the last 40 years, lupus patients still die on average 25 years earlier than the mean for women and men in the UK [2] .
and USA guidelines for LN management were published in 2012 [35] . As the disease causes significant morbidity and mortality, and can be associated with the rapid accumulation of damage if not promptly diagnosed, regularly monitored and appropriately treated, an up-to-date guideline, consistent with current National Health Service (NHS) practice, is warranted to help improve the outcome of this disease.
Objectives of the guideline
To provide comprehensive recommendations, covering the diagnosis, assessment, monitoring and treatment of mild, moderate and severe active lupus disease based on a literature review (to June 2015) for non-renal lupus, supplemented as necessary by UK expert opinion and consensus agreement, and that do not imply a legal obligation. We also provide a summary of and our strength of agreement (SOA) with the EULAR and European Renal AssociationEuropean Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for LN [4] in the full guideline [6] .
Target audience
The guidelines have been developed by a multidisciplinary group established by the British Society for Rheumatology (BSR) and consisting of academic and NHS consultants in rheumatology and nephrology, rheumatology trainees, a general practitioner, a clinical nurse specialist, a patient representative and a lay member. The target audience for the guideline includes rheumatologists and other clinicians who care for lupus patients, such as nephrologists, immunologists, dermatologists, emergency medicine practitioners, general practitioners, trainees, clinical nurse specialists and other allied health professionals.
Areas that the guideline does not cover This guideline does not cover the evidence for topical or systemic therapy for isolated cutaneous lupus, or paediatric lupus. Detailed dosing regimens are beyond the scope of this document. The management of the complications of lupus (including chronic fatigue, thrombosis, cardiovascular risk, osteoporosis, infection and cancer risk) are not discussed in detail and should be managed as for patients with similar risk factors according to relevant national and international guidelines.
Key recommendations from the guideline
The guideline was developed according to the BSR Protocol for Guidelines. The Scottish Intercollegiate Guidelines Network (SIGN) methodology [7] was used to determine the levels of evidence (LOEs) and grades of recommendations (GORs) for each statement, and these are shown in brackets below (LOE/GOR). For each recommendation, the strength of agreement (SOA) of the group was sought on a scale of 1 (no agreement) to 10 (complete agreement). The mean percentage agreement was calculated and is shown after each recommendation.
Treatment strategies are summarized in 
Assessment of SLE patients
(i) Clinical manifestations in SLE patients may be due to disease activity, damage, drug toxicity or the presence of co-morbidity. In the case of disease activity, it is important to ascertain whether this is due to active inflammation or thrombosis, as this will define treatment strategies (LOE 2 ++, GOR B, SOA 97%). Funding: No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in these guidelines.
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